Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8638253 | 0.92 | ALDH1A1 (0.50) | KMT2AALDH1A1KDM4EPOLBMMP8 | |
| SCHEMBL11900967 | 0.89 | MMP8 (0.49) | KMT2AALDH1A1KDM4EPOLBMMP8 | |
| SCHEMBL1891891 | 0.88 | KMT2A (0.42) | KMT2AALDH1A1KDM4EPOLBMMP8 | |
| SCHEMBL10701648 | 0.87 | NPC1 (0.50) | KMT2AALDH1A1KDM4EPOLBMMP8 | |
| SCHEMBL3804273 | 0.86 | KMT2A (0.47) | KMT2AALDH1A1KDM4EPOLBLMNA | |
| SCHEMBL6689379 | 0.85 | PPARG (0.48) | KMT2AALDH1A1KDM4ELMNATAAR1 | |
| SCHEMBL5329552 | 0.84 | TDP1 (0.49) | KMT2AALDH1A1MMP8NPC1TDP1 | |
| SCHEMBL3770522 | 0.82 | ALDH1A1 (0.43) | KMT2AALDH1A1KDM4EMMP8LMNA | |
| SCHEMBL11737506 | 0.82 | PPARG (0.49) | KMT2AALDH1A1KDM4EMAOBPPARG | |
| SCHEMBL3344661 | 0.82 | EPHX2 (0.47) | ALDH1A1KDM4EMMP8LMNANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11851435-B2 | PTGR2 inhibitors and their use | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2023-12-26 | — | — | US | disclosed |
| US-20230279008-A1 | PTGR2 INHIBITORS AND THEIR USE | NATIONAL TAIWAN UNIVERSITY (TW) | 2023-09-07 | — | — | US | disclosed |
| EP-1001774-B1 | USE OF PHOSPHOLAMBAN INHIBITORS FOR INCREASING CORONARY FLOW | ORION CORP (FI) | 2004-09-15 | — | — | EP | disclosed |
| US-6774103-B1 | Compounds for deactivating phospholamban function on Ca-ATPase (phospholamban inhibitors) | ORION CORPORATION (FI) | 2004-08-10 | — | — | US | disclosed |
| US-6538022-B1 | Three-dimensional structure of the cytosolic domain of phospholamban (PLB) and its active site from NMR data of sufficiently high resolution for the three-dimensional structure determination. rational drug design enabling the | ORION CORPORATION (FI) | 2003-03-25 | — | — | US | disclosed |
| EP-1039884-B1 | A METHOD FOR THE PREVENTION AND TREATMENT OF STUNNED MYOCARDIUM | ORION CORP (FI) | 2002-09-18 | — | — | EP | disclosed |
| US-6265421-B1 | DILATATION OF ARTERIES | ORION CORPORATION (FI) | 2001-07-24 | — | — | US | disclosed |
| EP-1039884-A1 | A METHOD FOR THE PREVENTION AND TREATMENT OF STUNNED MYOCARDIUM | ORION CORPORATION (FI) | 2000-10-04 | — | — | EP | disclosed |
| EP-1017691-A1 | BISETHERS OF 1-OXA, AZA AND THIANAPHTHALEN-2-ONES AS PHOSPHOLAMBAN INHIBITORS | ORION CORPORATION (ORION-YHTYMA OY) (FI) | 2000-07-12 | — | — | EP | disclosed |
| EP-1001774-A1 | USE OF PHOSPHOLAMBAN INHIBITORS TO INCREASING CORONARY FLOW | ORION CORPORATION (FI) | 2000-05-24 | — | — | EP | disclosed |
| US-5968959-A | ADMINISTERING PHOSPHOLAMBAN INHIBITOR | ORION CORPORATION (FI) | 1999-10-19 | — | — | US | disclosed |
| WO-1999030696-A1 | A METHOD FOR THE PREVENTION AND TREATMENT OF STUNNED MYOCARDIUM | ORION CORPORATION (FI) | 1999-06-24 | — | — | WO | disclosed |
| WO-1999015523-A1 | BISETHERS OF 1-OXA, AZA AND THIANAPHTHALEN-2-ONES AS PHOSPHOLAMBAN INHIBITORS | ORION CORPORATION (FI) | 1999-04-01 | — | — | WO | disclosed |
| WO-1999000132-A1 | USE OF PHOSPHOLAMBAN INHIBITORS FOR INCREASING CORONARY FLOW | ORION CORPORATION (FI) | 1999-01-07 | — | — | WO | disclosed |
| US-4014883-A | ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1977-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11851435-B2 | PTGR2 inhibitors and their use | PTGFR, PTGIR, PTGDR2 | KMT2A 4016/4885ALDH1A1 1177/4885KDM4E 4506/4885 |
| US-20230279008-A1 | PTGR2 INHIBITORS AND THEIR USE | PTGFR, PTGIR, PTGDR2 | KMT2A 4016/4885ALDH1A1 1177/4885KDM4E 4506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.